Puma Biotechnology Inc
PBYI
View Detailed Chart
6.940USD
+0.150+2.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
349.67MMarket Cap
9.25P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.21%
5 Days
+7.10%
1 Month
+18.43%
6 Months
+113.54%
Year to Date
+16.64%
1 Year
+140.14%
View Detailed Chart
TradingKey Stock Score of Puma Biotechnology Inc
Currency: USD Updated: 2026-02-06Key Insights
Puma Biotechnology Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 64 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 5.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Puma Biotechnology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Puma Biotechnology Inc Highlights
StrengthsRisks
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 230.47M.
Fairly Valued
The company’s latest PE is 9.25, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.99M shares, decreasing 18.40% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 4.28K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.12.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
5.000
Target Price
-26.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Puma Biotechnology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Puma Biotechnology Inc Info
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Ticker SymbolPBYI
CompanyPuma Biotechnology Inc
CEOAuerbach (Alan H)
Websitehttps://www.pumabiotechnology.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70821.260
+851.130 (+1.22%)
282.580
+22.390 (+8.61%)
2079.360
+27.630 (+1.35%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
